The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15903 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Alopecia Areata, Antibodies, Monoclonal, Humanized, Janus Kinase Inhibitors, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase‐4 (PDE‐4) inhibitors are recent therapies for alopecia areata (AA)—albeit, knowledge gaps exist for these agents' relative efficacy.
Objectives
We determined the relative efficacy and safety of monotherapy with the aforementioned agents in adults with AA.
Methods
The literature was systematically searched; we used data from randomized trials that investigated the agents' efficacy—as per Severity of Alopecia Tool (SALT) scores. Bayesian network meta‐analyses were used to determine relative efficacy and safety. Effect modification was determined using a generalized linear model on aggregate data; evidence quality was evaluated.
Results
Based on the surface under the cumulative ranking curve estimates obtained from multiple efficacy endpoints, regimens with the highest likelihood of achieving percent reduction in SALT scores, as well as a minimum 90%, 75% or 50% reduction in SALT scores are (in alphabetical order) baricitinib 4 mg once daily (QD), brepocitinib 60/30 mg QD, deuruxolitinib (CTP‐543) 12 mg twice daily (BID), ritlecitinib 200/50 mg QD, ruxolitinib 20 mg BID and tofacitinib 5 mg BID. In contrast, dupilumab subcutaneous injections administered weekly and apremilast 30 mg BID were less likely to be effective. Discontinuation due to any adverse event was the least likely with oral JAK inhibitors, and more likely with dupilumab and apremilast.
Conclusions
Our results support the conduct of high‐quality comparative trials to determine whether JAK inhibitors are more effective and safer than PDE4 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
- Fredric Brandt Endowed Professor of Dermatology, University of Miami, Miami, Florida, USA.
ORCID-Profile: Aditya K Gupta
Zitieren
APA
Gupta, A. K., Wang, T., Bamimore, M. A., Piguet, V., & Tosti, A. (2023). The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15903
Vancouver
Gupta AK, Wang T, Bamimore MA, Piguet V, Tosti A. The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15903
BibTeX
@article{Gupta2023,
author = {Gupta, Aditya K and Wang, Tong and Bamimore, Mary A and Piguet, Vincent and Tosti, Antonella},
title = {The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15903}
}
EUVIMED